Recent Updates
Recently added Catalysts

SNK01

Phase 2

Plaque Psoriasis | Biologics | Dermatology |NKGen Biotech, Inc.|Trials Updated: Jun 26, 2020

SNK01 development status

Highest phase Phase 2 (NCT07228078)
Phase scored for NKGNPhase 1
Registered trials 7 across 1 sponsor since Mar 2019

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment9

FDA Designations

No designations recorded

SNK01 clinical trials

SNK01 · 1 trial · 1 indication

Phase 1 1
NCT03894579Autologous Natural Killer Cells in Subjects With Plaque PsoriasisPlaque Psoriasis
COMPLETED9 Analytics
PHASE1COMPLETED
Autologous Natural Killer Cells in Subjects With Plaque Psoriasis
Plaque Psoriasis
NCT038945799
Unlock trial analytics

Study Endpoints

Primary Endpoints

The primary endpoint for safety is the dose-limiting toxicity (DLT)
From enrollment to end of treatment at 8 Weeks

DLT is a TEAE of grade ≥3 considered related to SNK01

Secondary Endpoints

Preliminary Efficacy by Physician Global Assessment (PGA)
From enrollment to end of treatment at 8 Weeks
Preliminary Efficacy by Psoriasis Area and Severity Index (PASI)
From enrollment to end of treatment at 8 Weeks
Secondary Safety Measures: Other Non-DLT Adverse Events
From enrollment to end of treatment at 8 Weeks
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
SNK01EXPERIMENTALSNK01 infused weekly for 4 consecutive weeks

Interventions

NameTypeDescription
Study Product: SNK01BIOLOGICALSNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: Subjects will be considered eligible for participation in the study if all the following inclusion criteria are satisfied: 1. Informed consent obtained before any "trial-related activities" (Trial-related activities are any procedure that would not have been performed during no...

Countries:Mexico
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

NKGen Biotech, Inc. (NKGN)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with SCompanies A to ZEvery biotech and pharma company we track